Advertisement

Related Videos

Welcome and Introduction to Vi3C

Opportunities to Optimize Cancer Policies Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jan
13
Today In Oncology
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive mCRPC
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
Do GLP-1 RAs Reduce the Risk of Developing Colorectal Cancer More Than Aspirin
High Neighborhood Fast Food Expenditure and Early-Onset Colorectal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo